{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:27:57Z","timestamp":1783607277811,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.tube.2023.102425","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T15:25:40Z","timestamp":1698074740000},"page":"102425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72\/AS01"],"prefix":"10.1016","volume":"143","author":[{"given":"Nadia","family":"Ouaked","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Demoiti\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Godfroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Vanloubbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane T.","family":"Temmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2023.102425_bib1","series-title":"Global tuberculosis report 2022","year":"2022"},{"key":"10.1016\/j.tube.2023.102425_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nri.2017.69","article-title":"Heterogeneity in tuberculosis","volume":"17","author":"Cadena","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.tube.2023.102425_bib3","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijid.2022.03.011","article-title":"The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB","volume":"124","author":"Chakaya","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2023.102425_bib4","first-page":"73","article-title":"BCG vaccines: WHO position paper \u2013 February 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.tube.2023.102425_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG - implications for a novel tuberculosis vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2023.102425_bib6","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines","volume":"12","author":"Harris","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.tube.2023.102425_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/joim.13197","article-title":"New tuberculosis vaccines: advances in clinical development and modelling","volume":"288","author":"Weerasuriya","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.tube.2023.102425_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12865-015-0119-7","article-title":"Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens","volume":"16","author":"Mortier","year":"2015","journal-title":"BMC Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib10","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/IAI.67.8.3998-4007.1999","article-title":"Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis","volume":"67","author":"Skeiky","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2023.102425_bib11","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/IAI.67.6.2941-2950.1999","article-title":"Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family","volume":"67","author":"Dillon","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2023.102425_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013120","article-title":"Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: results from a phase II randomized controlled trial","volume":"97","author":"Kumarasamy","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tube.2023.102425_bib13","doi-asserted-by":"crossref","first-page":"e2459","DOI":"10.1097\/MD.0000000000002459","article-title":"A randomized, controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tube.2023.102425_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2023.102425_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/QAD.0000000000000343","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial","volume":"28","author":"Thacher","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.tube.2023.102425_bib16","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2023.102425_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fimmu.2018.00564","article-title":"Adjuvant-associated peripheral blood mRNA profiles and kinetics induced by the adjuvanted recombinant protein candidate tuberculosis vaccine M72\/AS01 in Bacillus Calmette-Gu\u00e9rin-vaccinated adults","volume":"9","author":"van den Berg","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2023.102425_bib19","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2023.102425_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","author":"Day","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2023.102425_bib21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-013-9949-3","article-title":"A randomized, controlled dose-finding phase II study of the M72\/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults","volume":"33","author":"Montoya","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib22","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2023.102425_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276505","article-title":"Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses","volume":"17","author":"Coccia","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2023.102425_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14760584.2019.1593143","article-title":"Designing tuberculosis vaccine efficacy trials - lessons from recent studies","volume":"18","author":"Ginsberg","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2023.102425_bib26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/infdis\/jiaa421","article-title":"A Phase IIa controlled human malaria infection and immunogenicity study of RTS,S\/AS01E and RTS,S\/AS01B delayed fractional dose regimens in malaria-naive adults","volume":"222","author":"Moon","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2023.102425_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41541-021-00337-0","article-title":"Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants","volume":"6","author":"Budroni","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib28","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1038\/nm1216","article-title":"Can successful vaccines teach us how to induce efficient protective immune responses?","volume":"11","author":"Lambert","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2023.102425_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830482","article-title":"Leveraging antibody, B cell and fc receptor interactions to understand heterogeneous immune responses in tuberculosis","volume":"13","author":"Carpenter","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/854507","article-title":"Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers","volume":"2015","author":"Lyadova","year":"2015","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.tube.2023.102425_bib31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2017.01262","article-title":"Polyfunctional CD4+ T cells as targets for tuberculosis vaccination","volume":"8","author":"Lewinsohn","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"npj Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib33","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1073\/pnas.1906613117","article-title":"Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans","volume":"117","author":"Ellebedy","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2023.102425_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4130","article-title":"Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine","volume":"14","author":"Arunachalam","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2023.102425_bib35","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41467-022-29219-2","article-title":"Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates","volume":"13","author":"Pavot","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.tube.2023.102425_bib36","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1038\/s41467-022-34728-1","article-title":"Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19","volume":"13","author":"Gobeil","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.tube.2023.102425_bib37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.vaccine.2014.01.008","article-title":"Cross-neutralizing antibodies elicited by the Cervarix\u00ae human papillomavirus vaccine display a range of Alpha-9 inter-type specificities","volume":"32","author":"Bissett","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.tube.2023.102425_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/14760584.2019.1579647","article-title":"Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types","volume":"18","author":"Ryser","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00969-16","article-title":"The enigmatic PE\/PPE multigene family of mycobacteria and tuberculosis vaccination","volume":"85","author":"Brennan","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2023.102425_bib40","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.3390\/ijms21113985","article-title":"Mycobacterial virulence factors: surface-exposed lipids and secreted proteins","volume":"21","author":"Ly","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tube.2023.102425_bib41","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1007\/s00253-015-6962-x","article-title":"A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection","volume":"99","author":"Yuan","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.tube.2023.102425_bib42","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","article-title":"Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells","volume":"190","author":"Lindenstr\u00f8m","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib43","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1038\/s41598-017-08526-5","article-title":"Delayed fractional dose regimen of the RTS,S\/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis","volume":"7","author":"Chaudhury","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2023.102425_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51889","article-title":"A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses","volume":"9","author":"Pallikkuth","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.tube.2023.102425_bib45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.medj.2021.10.003","article-title":"Delayed fractional dosing with RTS,S\/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and Pf16-specific antibodies","volume":"2","author":"Das","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.tube.2023.102425_bib46","series-title":"Novel compositions and methods (patent). Patent application no. PCT\/EP2009\/059586. Patent no. WO2010\/010180 A1; Canadian Patents Database 2731549 2015-11-19","author":"Brown","year":"2010"},{"key":"10.1016\/j.tube.2023.102425_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107898","article-title":"Multifunctional T cell response in active pulmonary tuberculosis patients","volume":"99","author":"Qin","year":"2021","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.tube.2023.102425_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247990","article-title":"Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model","volume":"16","author":"Baldwin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2023.102425_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52146-0","article-title":"Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model","volume":"9","author":"Kwon","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2023.102425_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137858","article-title":"Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment","volume":"5","author":"Shanmugasundaram","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.tube.2023.102425_bib51","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.immuni.2022.04.004","article-title":"Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control","volume":"55","author":"Gideon","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.tube.2023.102425_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009096","article-title":"Protective efficacy of an attenuated Mtb \u0394LprG vaccine in mice","volume":"16","author":"Martinot","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2023.102425_bib53","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.celrep.2018.04.003","article-title":"STING-Activating adjuvants elicit a Th17 immune response and protect against Mycobacterium tuberculosis infection","volume":"23","author":"Van Dis","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.tube.2023.102425_bib54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/mi.2014.136","article-title":"Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge","volume":"8","author":"Monin","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004099","article-title":"Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection","volume":"10","author":"Gopal","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2023.102425_bib56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/imm.12130","article-title":"Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection","volume":"140","author":"Freches","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.tube.2023.102425_bib57","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","article-title":"Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung","volume":"184","author":"Okamoto Yoshida","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni.2053","article-title":"The development of inducible bronchus-associated lymphoid tissue depends on IL-17","volume":"12","author":"Rangel-Moreno","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-020-00255-7","article-title":"Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis","volume":"5","author":"Counoupas","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib61","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4049\/jimmunol.1302258","article-title":"Role of Th1\/Th17 balance regulated by T-bet in a mouse model of Mycobacterium avium complex disease","volume":"192","author":"Matsuyama","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/eji.201141569","article-title":"IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination","volume":"42","author":"Gopal","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.tube.2023.102425_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-020-0160-2","article-title":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial","volume":"5","author":"Blank","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.tube.2023.102425_bib64","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1073\/pnas.1500475112","article-title":"Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination","volume":"112","author":"Akondy","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2023.102425_bib65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(22)00273-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial","volume":"22","author":"Samuels","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2023.102425_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: a randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2023.102425_bib67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2023.102425_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/vaccines9030289","article-title":"Short or long interval between priming and boosting: does it impact on the vaccine immunogenicity?","volume":"9","author":"Pettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.tube.2023.102425_bib69","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1080\/21645515.2021.1968214","article-title":"Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents","volume":"17","author":"Vesikari","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.tube.2023.102425_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106051","article-title":"Design of a peptide-based vaccine from late stage specific immunogenic cross-reactive antigens of PE\/PPE proteins of Mycobacterium tuberculosis","volume":"168","author":"Medha","year":"2022","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.tube.2023.102425_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040890","article-title":"Conserved immune recognition hierarchy of mycobacterial PE\/PPE proteins during infection in natural hosts","volume":"7","author":"Vordermeier","year":"2012","journal-title":"PLoS One"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:48:13Z","timestamp":1761468493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979223001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":71,"alternative-id":["S1472979223001233"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2023.102425","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72\/AS01","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2023.102425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102425"}}